SynthesisFrontiers in nephrology2026
Impact of hematuria on long term kidney outcomes in adults with immunoglobulin A nephropathy: a systematic literature review and meta-analysis.
Synthesis in Frontiers in nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hematuria is the most common clinical manifestation of Immunoglobulin A nephropathy (IgAN) and has been associated with adverse long-term kidney outcomes, although its prognostic significance has not been clearly established. This systematic literature review and meta-analysis aimed to evaluate whether hematuria is a prognostic marker of long-term kidney outcomes. Methods: A search of PubMed/MEDLINE and Embase (January 2005 to June 2025) identified studies assessing persistent or single-timepoint measurement of microhematuria or macrohematuria in relation to kidney outcomes. Studies meeting predefined criteria were qualitatively synthesized, and those with comparable outcome definitions were included in meta-analyses using random-effects models. Results: Forty-three studies were included in the systematic literature review, of which 15 study entries from 13 publications were included in meta-analyses. Across studies, persistent microhematuria was consistently associated with worse long-term kidney outcomes. In pooled analyses, microhematuria (both persistent and single-timepoint measurements) was associated with an increased risk of end-stage kidney disease or related outcomes (hazard ratio [HR] 2.33, 95% confidence interval [CI] 1.94-2.80), with a stronger and consistent association observed for persistent microhematuria (HR 2.57, 95% CI 1.94-3.41). Single-timepoint measurement of microhematuria showed a nonsignificant directional association with substantial variability across studies, whereas macrohematuria (predominantly measured at a single timepoint) was associated with improved kidney outcomes (HR 0.56, 95% CI 0.37-0.83). Discussion: These findings support persistent microhematuria as a strong and consistent predictor of kidney failure in IgAN, substantiating its role as a clinically relevant prognostic marker.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.